Welm A - Search Results

1

Inhibiting an RBM39/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation.

Puvvula PK, Yu Y, Sullivan KR, Eyob H, Rosenberg J, Welm A, Huff C, Moon AM. Puvvula PK, et al. Among authors: welm a. Cell Rep. 2021 Jun 1;35(9):109156. doi: 10.1016/j.celrep.2021.109156. Cell Rep. 2021. PMID: 34077726 Free article.

2

TGFbeta primes breast tumor cells for metastasis.

Welm AL. Welm AL. Cell. 2008 Apr 4;133(1):27-8. doi: 10.1016/j.cell.2008.03.012. Cell. 2008. PMID: 18394984 Free article.

3

The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.

Kretschmann KL, Eyob H, Buys SS, Welm AL. Kretschmann KL, et al. Curr Drug Targets. 2010 Sep;11(9):1157-68. doi: 10.2174/138945010792006825. Curr Drug Targets. 2010. PMID: 20545605 Review.

4

Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.

Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL. Liu X, et al. Genes Cancer. 2011 Jul;2(7):753-62. doi: 10.1177/1947601911421924. Genes Cancer. 2011. PMID: 22207901 Free PMC article.

5

Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Eyob H, et al. Among authors: welm al. Cancer Discov. 2013 Jul;3(7):751-60. doi: 10.1158/2159-8290.CD-12-0480. Epub 2013 Apr 23. Cancer Discov. 2013. PMID: 23612011 Free PMC article.

6

RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses.

Eyob H, Ekiz HA, Welm AL. Eyob H, et al. Oncoimmunology. 2013 Sep 1;2(9):e25670. doi: 10.4161/onci.25670. Epub 2013 Aug 14. Oncoimmunology. 2013. PMID: 24327933 Free PMC article.

7

The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.

Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm AL. Cunha S, et al. Among authors: welm al. Cell Rep. 2014 Jan 16;6(1):141-54. doi: 10.1016/j.celrep.2013.12.010. Epub 2014 Jan 2. Cell Rep. 2014. PMID: 24388747 Free PMC article.

8

Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.

Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC. Chaturvedi A, et al. Among authors: welm al. Mol Biol Cell. 2014 Sep 15;25(18):2695-709. doi: 10.1091/mbc.E14-01-0007. Epub 2014 Jul 23. Mol Biol Cell. 2014. PMID: 25057021 Free PMC article.

9

Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En Masse.

Viswanath P, Welm AL. Viswanath P, et al. Cancer Cell. 2021 Feb 8;39(2):148-150. doi: 10.1016/j.ccell.2021.01.017. Cancer Cell. 2021. PMID: 33561396 Free article.

10

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities.

Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK. Knudsen ES, et al. Cell Rep. 2022 Mar 1;38(9):110448. doi: 10.1016/j.celrep.2022.110448. Cell Rep. 2022. PMID: 35235778 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters